Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema

Catharina Busch,Dinah Zur,Samantha Fraser-Bell,Inês Laíns,Ana Rita Santos,Marco Lupidi,Carlo Cagini,Pierre-Henry Gabrielle,Aude Couturier,Valérie Mané-Tauty,Ermete Giancipoli,Giuseppe D’Amico Ricci,Zafer Cebeci,Patricio J. Rodríguez-Valdés,Voraporn Chaikitmongkol,Atchara Amphornphruet,Isaac Hindi,Kushal Agrawal,Jay Chhablani,Anat Loewenstein,Matias Iglicki,Matus Rehak

Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema

2018

Aims To compare functional and anatomical outcomes of continued anti-vascular endothelial growth factor (VEGF) therapy versus dexamethasone (DEX) implant in eyes with refractory diabetic macular edema (DME) after three initial anti-VEGF injections in a real-world setting.

Keywords:

Cardiology
Internal medicine
Dexamethasone
Endocrinology
Diabetes mellitus
Growth factor
Implant
VEGF receptors
Macular edema
Medicine
Ophthalmology
diabetic macular edema
Refractory
anti vegf

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations